These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36912060)

  • 21. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial.
    Spiera R; Unizony SH; Bao M; Luder Y; Han J; Pavlov A; Stone JH
    Semin Arthritis Rheum; 2021 Apr; 51(2):469-476. PubMed ID: 33784598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tocilizumab in giant cell arteritis: Multicenter open-label study of 22 patients.
    Loricera J; Blanco R; Hernández JL; Castañeda S; Mera A; Pérez-Pampín E; Peiró E; Humbría A; Calvo-Alén J; Aurrecoechea E; Narváez J; Sánchez-Andrade A; Vela P; Díez E; Mata C; Lluch P; Moll C; Hernández Í; Calvo-Río V; Ortiz-Sanjuán F; González-Vela C; Pina T; González-Gay MÁ
    Semin Arthritis Rheum; 2015 Jun; 44(6):717-23. PubMed ID: 25697557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
    Yoshifuji H
    Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vision loss in patients with giant cell arteritis treated with tocilizumab.
    Amsler J; Kysela I; Tappeiner C; Seitz L; Christ L; Scholz G; Stalder O; Kollert F; Reichenbach S; Villiger PM
    Arthritis Res Ther; 2021 Mar; 23(1):92. PubMed ID: 33752737
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of the efficacy and safety of tocilizumab in patients over 80 years old with giant cell arteritis.
    de Boysson H; Le Besnerais M; Blaison F; Daumas A; Jarrot PA; Perrin F; Tieulié N; Maria A; Duffau P; Gombert B; Samson M; Espitia O; Lambert M; Mékinian A; Aouba A;
    Arthritis Res Ther; 2021 May; 23(1):143. PubMed ID: 34011407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy.
    Miyabe C; Miyabe Y; Strle K; Kim ND; Stone JH; Luster AD; Unizony S
    Ann Rheum Dis; 2017 May; 76(5):898-905. PubMed ID: 27927642
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Giant cell arteritis with ocular involvement successfully treated with tocilizumab and very short-course glucocorticoids: A case report.
    Khanna RK; Hage R; Lecler A; Sene T; Vignal-Clermont C; Clavel-Refregiers G
    J Fr Ophtalmol; 2021 Apr; 44(4):481-484. PubMed ID: 33712335
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tocilizumab-associated posterior reversible encephalopathy syndrome in giant-cell arteritis - case report.
    Butryn M; Mewes S; Feist E; Beuing O; Müller C; Neumann J
    BMC Neurol; 2021 Jun; 21(1):228. PubMed ID: 34157987
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tocilizumab as an add-on therapy to glucocorticoids during the first 3 months of treatment of Giant cell arteritis: A prospective study.
    Samson M; Devilliers H; Ly KH; Maurier F; Bienvenu B; Terrier B; Charles P; Guillevin L; Besancenot JF; Liozon E; Fauchais AL; Loffroy R; Binquet C; Audia S; Seror R; Mariette X; Bonnotte B
    Eur J Intern Med; 2018 Nov; 57():96-104. PubMed ID: 30054122
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse Risk and Safety of Long-Term Tocilizumab Use Among Patients With Giant Cell Arteritis: A Single-Enterprise Cohort Study.
    Samec MJ; Rakholiya J; Langenfeld H; Crowson CS; Abril A; Wang B; Mertz L; Rodriguez-Pla A; Bansal P; Burke M; Jaquith J; Weyand C; Warrington KJ; Koster MJ
    J Rheumatol; 2023 Oct; 50(10):1310-1317. PubMed ID: 37321636
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.
    Hellmich B; Águeda AF; Monti S; Luqmani R
    Curr Rheumatol Rep; 2020 Oct; 22(12):84. PubMed ID: 33044642
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tocilizumab for giant cell arteritis.
    Antonio AA; Santos RN; Abariga SA
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD013484. PubMed ID: 34420204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Giant cell arteritis successfully treated with subcutaneous tocilizumab monotherapy.
    Higashida-Konishi M; Akiyama M; Shimada T; Hama S; Oshige T; Izumi K; Oshima H; Okano Y
    Rheumatol Int; 2023 Mar; 43(3):545-549. PubMed ID: 36152056
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis.
    Monti S; Águeda AF; Luqmani RA; Buttgereit F; Cid M; Dejaco C; Mahr A; Ponte C; Salvarani C; Schmidt W; Hellmich B
    RMD Open; 2019; 5(2):e001003. PubMed ID: 31673411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Cost-Effectiveness of Tocilizumab (Actemra) Therapy in Giant Cell Arteritis.
    Jogimahanti AV; Kini AT; Irwin LE; Lee AG
    J Neuroophthalmol; 2021 Sep; 41(3):342-350. PubMed ID: 34415267
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained remission after long-term biological therapy in patients with large vessel vasculitis: an analysis of ten cases.
    Vinicki JP; García-Vicuña R; Arredondo M; López-Bote JP; García-Vadillo JA; Castañeda S; Álvaro-Gracia JM
    Reumatol Clin; 2017; 13(4):210-213. PubMed ID: 27499427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis.
    Reichenbach S; Adler S; Bonel H; Cullmann JL; Kuchen S; Bütikofer L; Seitz M; Villiger PM
    Rheumatology (Oxford); 2018 Jun; 57(6):982-986. PubMed ID: 29529280
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world Risk of Relapse of Giant Cell Arteritis Treated With Tocilizumab: A Retrospective Analysis of 43 Patients.
    Clément J; Duffau P; Constans J; Schaeverbeke T; Viallard JF; Barcat D; Vernhes JP; Sailler L; Bonnet F
    J Rheumatol; 2021 Sep; 48(9):1435-1441. PubMed ID: 33589561
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia.
    Robinson L; Hamden M; Griggs K; Simon S; Hill C; Limaye V; Proudman S
    Intern Med J; 2024 Jul; 54(7):1228-1232. PubMed ID: 38953308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An agent-to-agent real life comparison study of tocilizumab versus abatacept in giant cell arteritis.
    Rossi D; Cecchi I; Sciascia S; Naretto C; Alpa M; Roccatello D
    Clin Exp Rheumatol; 2021; 39 Suppl 129(2):125-128. PubMed ID: 33635228
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.